glp-1 with medicaid McKee's proposed FY2027 budget drops drugs for weight loss from • Rhode Island Current Dr Blitz: Medicare Deal for

Tirzepatide works by activating GLP-1 and GIP receptors in your gut and brain, which can amplify sensitivity to stimulants like caffeine

Best practice: Match the peptide to the severity of the metabolic model (Standard obesity/T2D = Tirzepatide, Severe obesity/Lipolysis = Retatrutide)

Furthermore, the Endocrine Societys obesity guideline recommends that patients with obesity in the absence of diabetes should discontinue weight-loss medications if safety or tolerability issues arise, and consider other therapeutic options

Retrieved from Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Retatrutide is emerging as a novel peptide-based weight loss medication with a unique triple-action mechanism

The Insurance Reality Check Both medications usually require prior authorization (insurance company paperwork), and both are covered similarly